Harmony's WAKIX Sales Rise 12% To $268.9 Million, But Milestone And Royalty Costs Trim Profit

The narcolepsy drugmaker held its 2026 WAKIX guidance at $1.0 billion to $1.04 billion and posted early safety data for BP-205.

Share
Harmony's WAKIX Sales Rise 12% To $268.9 Million, But Milestone And Royalty Costs Trim Profit

Harmony Biosciences, which sells the narcolepsy drug WAKIX, said Wednesday that WAKIX net revenue rose 12% in the third quarter to $268.9 million, while net income slipped to $48.2 million from $50.9 million a year earlier. The company reiterated its full-year WAKIX revenue guidance and reported preliminary safety data on its experimental drug BP-205, according to an 8-K filing.

Sales up, earnings per share down

WAKIX revenue compared with $239.5 million in the third quarter of 2025. The estimated average patient count grew by 400 to 9,350, and the company said five of the last six quarters have brought more than 400 patient additions.

Diluted earnings per share fell to $0.81 from $0.87. The company blamed higher milestone charges and new royalty charges tied to the MSN license.

Research and development spending rose 30% to $71.7 million, mostly on a $25.0 million charge for a milestone under the MSN license agreement. Cost of product sold climbed to $80.7 million, or 30% of revenue against 25% a year earlier, mainly because of new royalties under the Novitium license. Total operating expenses reached $134.0 million, up 17%.

For the first nine months, net product revenue was $745.6 million and net income $156.1 million, up from $624.7 million and $136.2 million.

A drugmaker built on one product

Harmony is a neuroscience company focused on rare neurological diseases. WAKIX (pitolisant) is its commercial product, a once-daily tablet for excessive daytime sleepiness and cataplexy in narcolepsy. It is the only approved narcolepsy treatment not scheduled as a controlled substance, the company says.

Management reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion. Cash and investments stood at $1,051.6 million on September 30, against $882.5 million at the end of 2025.

BP-205 safety data and the patent calendar

In a 14-day study of BP-205, an orexin-2 receptor agonist, 94 healthy volunteers took once-daily doses from 0.1 mg to 3 mg against a placebo. The company reported no liver or visual adverse events and no serious or severe adverse events. Headache was the most common problem, in about 25% of participants.

Phase 1b data in sleep-deprived healthy volunteers are expected in the first quarter of 2027, with Phase 2 studies in multiple CNS indications to start by mid-2027.

The FDA's target decision date for the pitolisant GR tablet is April 1, 2027. A ruling in the generic-filer patent trial is expected around February 2027, and a preliminary injunction hearing in the amorphous-form case is set for January 26, 2027. Harmony says it has settled with six of seven generic filers and expects WAKIX exclusivity to March 2030.

Peter Anastasiou, now chief operating officer, becomes CEO on January 1, 2027. Jeffrey Dayno retires December 31.

The next hard dates are January 26, 2027 for the injunction hearing and April 1, 2027 for the FDA's decision on pitolisant GR.

Sources

More on Harmony Biosciences

All Harmony Biosciences (HRMY) coverage →